Please login to the form below

Not currently logged in
Email:
Password:

Novartis in TB research deal

Novartis has entered into a research deal with the Global Alliance for TB Drug Development (TB Alliance) to pursue an R&D programme to discover novel treatments for the disease
Novartis has entered into a research deal with the Global Alliance for TB Drug Development (TB Alliance) to pursue an R&D programme to discover novel treatments for the disease.

The five-year research agreement is aimed at developing new medicines to treat tuberculosis (TB) and multi-drug resistant TB (MDR TB), plus faster acting drug regimens that are easier for patients to complete. Under the terms of the new deal, the Novartis Institute for Tropical Diseases (NITD) and the TB Alliance will share information and data about TB drug discovery projects.

Dr Jerome Premmereur, president and CEO of the TB Alliance, said that the global TB crisis is showing no signs of abating and that novel treatments to combat the problem are desperately needed.

"We are confident our collaboration with NITD will not only produce promising anti-TB drug candidates, but will serve as an industry model in combining resources, expertise and willpower to tackle one of the greatest public health threats of our time," he said.

According to data from the World Health Organisation (WHO), there were 490,000 cases of MDR TB in 2006 and the disease claimed the lives of over 1.5 million people globally during the same year.

Current estimates suggest that one-third of the world's population is infected with mycobacterium tuberculosis (M.tb), the bacteria that can lead to TB. It is the prominent cause of death among HIV-infected patients with weak immune systems.

Novartis says that the current TB drug regimen is not compatible in patients with HIV/AIDS and hopes that the joint discovery programme will help produce medicines that can be used on HIV/AIDS patients.

"Our dedicated research team will leverage our expertise gained throughout the past six years of NITD's TB efforts in partnership with the TB Alliance," said Paul Herring, chairman of NITD and head of corporate research at Novartis.

24th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics